Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
USD961376 | REGENERON PHARMACEUTICALS, INC. | Packaging |
Aug, 2040
(16 years from now) | |
US11439758 | REGENERON PHARMACEUTICALS, INC. | Devices and methods for precision dose delivery |
Aug, 2040
(16 years from now) | |
US11433186 | REGENERON PHARMACEUTICALS, INC. | Devices and methods for precision dose delivery |
Aug, 2040
(16 years from now) | |
USD961377 | REGENERON PHARMACEUTICALS, INC. | Packaging |
Aug, 2040
(16 years from now) | |
US11472861 | REGENERON PHARMACEUTICALS, INC. | Methods for producing aflibercept in chemically defined media having reduced aflibercept variants |
Aug, 2040
(16 years from now) | |
US11459374 | REGENERON PHARMACEUTICALS, INC. | Anti-VEGF protein compositions and methods for producing the same |
Aug, 2040
(16 years from now) | |
US11459373 | REGENERON PHARMACEUTICALS, INC. | Anti-VEGF protein compositions and methods for producing the same |
Aug, 2040
(16 years from now) |
Ingredients: AFLIBERCEPT
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic